Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
AJANI, JAFFER A
One or more keywords matched the following items that are connected to AJANI, JAFFER A
Item TypeName
Academic Article Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma.
Concept B7-H1 Antigen
Academic Article Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?
Academic Article Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
Academic Article Epstein-Barr virus-associated gastric cancer: disease that requires special approach.
Academic Article Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
Academic Article ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
Academic Article Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Academic Article 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy.
Academic Article Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Academic Article Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.
Academic Article PD-L1 expression and overall survival in Asian and western patients with gastric cancer.
Academic Article Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
Academic Article Tissue-Based PD-L1 Expression Is the Strongest Predictor of Overall Survival Benefit From ICI in Advanced Gastroesophageal Cancer-Reply.
Academic Article Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma.
Search Criteria
  • B7 2 Antigen